Trump Declares Stiff Future Tariffs on Generic Drugs to Drive US Production

US President Donald Trump has unveiled a sweeping new trade policy impacting generic drug imports, announcing phased tariffs that will escalate to 200% by August 2029. Starting August 1, 2026, generic drugs will remain tariff-free for two years, but this will be followed by a 100% duty from August 2028 for one year, and then a hefty 200% tariff thereafter. The move, announced on Truth Social, aims to aggressively 'reshore' pharmaceutical production to the United States and reduce the nation's heavy reliance on foreign-made medicines. This aggressive stance on generic drugs expands Trump's broader strategy to fortify domestic pharmaceutical manufacturing, building on earlier tariffs imposed on patented and branded medicines. The policy is a direct challenge to major generic drug exporters like India, China, and European Union countries, which supply a significant portion of the generic medicines used in the US, estimated to be around 70% of the 90% of prescriptions filled. The announcement comes despite recent Supreme Court rulings that found some past tariffs unlawful, raising questions about the legal authority for these new, steep duties. The coming two-year grace period is intended to give pharmaceutical companies time to establish or expand manufacturing facilities within the US, with penalties for those that fail to comply. The long-term implications are significant, potentially disrupting global supply chains, increasing drug costs, and impacting patient access to affordable medicines. Observers will be watching closely for how pharmaceutical giants and major exporting nations like India respond to this ultimatum, and whether the proposed tariffs will face legal challenges or be subject to negotiation.